Drug Information

Drug General Information
Drug ID
D0W2HD
Former ID
DNC014900
Drug Name
Mogamulizumab
Drug Type
Monoclonal antibody
Indication Discovery agent Phase 2 [523931], [541612]
Target and Pathway
Target(s) C-Cchemokine receptor type 4 Target Info Inhibitor [531298]
KEGG Pathway Cytokine-cytokine receptor interaction
Chemokine signaling pathway
Viral carcinogenesis
PANTHER Pathway Inflammation mediated by chemokine and cytokine signaling pathway
Reactome Chemokine receptors bind chemokines
G alpha (i) signalling events
WikiPathways GPCRs, Class A Rhodopsin-like
Peptide GPCRs
GPCR ligand binding
GPCR downstream signaling
References
Ref 523931ClinicalTrials.gov (NCT01611142) Study of KW-0761 (Mogamulizumab) in Subjects With Previously Treated Peripheral T-cell Lymphoma (PTCL). U.S. National Institutes of Health.
Ref 541612(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6477).
Ref 531298Curr Opin Mol Ther. 2010 Dec;12(6):770-9.Mogamulizumab, a humanized mAb against C-C chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.